echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > The 4th domestically produced!

    The 4th domestically produced!

    • Last Update: 2021-06-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 24, the official website of the State Food and Drug Administration showed that sunitinib malate capsules of Chia Tai Tianqing Pharmaceutical Group were approved for marketing, and the product was the fourth domestically approved product.


    Source: One-click search on Mi Nei.


    Data show that sunitinib malate capsules were developed by Pfizer and are used for inoperable advanced renal cell carcinoma, imatinib mesylate treatment failure or intolerable gastrointestinal stromal tumors and unresectable high metastasis Differentiated and advanced pancreatic neuroendocrine tumors.


    Sales of sunitinib capsules in Chinese public medical institutions and physical pharmacies in Chinese cities

    Source: Mi Nei Net Database

    According to data from Minei.


    At present, there are 5 manufacturers of sunitinib malate capsules.


    Source: official website of the State Food and Drug Administration, Mi Nei.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.